Galen Clinic

Galen Clinic advances treatment for autoimmune neuromuscular disorders, concentrating on conditions such as generalized Myasthenia Gravis and chronic inflammatory demyelinating polyneuropathy, by testing innovative antibody‑based therapies and novel delivery methods.

• Evaluation of new antibody therapies for seronegative Myasthenia Gravis
• Subcutaneous formulation of efgartigimod for CIDP patients
• Long‑term safety and efficacy of batoclimab in active CIDP
• Assessment of zilucoplan in maintaining clinical response in generalized Myasthenia Gravis
• Comparative dosing regimens of efgartigimod IV in Myasthenia Gravis

With 20 active studies, the site aims to broaden therapeutic options and improve patient outcomes for immune‑mediated diseases, while ensuring safety and tolerability of emerging treatments.

Research at Galen Clinic targets neurodegenerative and demyelinating disorders, including Alzheimer disease, multiple sclerosis, and trigeminal neuralgia, focusing on disease‑modifying agents, cognitive enhancement, and pain relief.

• Disease‑modifying therapy assessment for relapsing multiple sclerosis
• Cognitive benefit of GV1001 in mild‑to‑moderate Alzheimer disease
• Pain reduction in trigeminal neuralgia using basimglurant
• Management of agitation in Alzheimer’s dementia with AVP‑786
• Early intervention study of donanemab in symptomatic Alzheimer disease

The trials strive to slow disease progression, enhance cognition, and alleviate symptoms, offering patients access to cutting‑edge therapies within a supportive clinical environment.